Escherichia coli (Migula) Castellani and Chalmers
Escherichia coli (Migula) Castellani and Chalmers
规格:
货期:
编号:TS215124
品牌:Testobio
| 产品名称： | Escherichia coli (Migula) Castellani and Chalmers |
|---|---|
| 商品货号： | TS215124 |
| Reports： | Upon your purchase of this product, you will receive a report containing MIC values, a susceptibility profile, and the DNA sequence information for predicted annotated antibiotic resistance genes and 16S rRNA genes. This report will be provided in multiple formats (.pdf, .txt, .xls, .zip). |
| Deposited As： | Escherichia coli |
| Classification： | Enterobacteriaceae, Escherichia |
| Strain Designations： | 1099705 |
| Application： | Drug discovery and development Development of molecular-based detection assays Development of updated sterility protocols |
| Isolation： | Urine |
| Isolation Date： | 2014 |
| Geographic Source： | Czech Republic |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen |
| Storage Conditions： | -80°C or colder |
| Preceptrol®： | no |
| Annotated Genes： | AAC(3)-IIa aadA5 acrA acrB acrD acrE acrF APH(3\)-Ib APH(6)-Id baeR CMY-47 CTX-M-14 emrB emrE macA macB marA mdtB mdtC mdtF mexB msbA TEM-1 tet(G) tolC |
| Type Strain： | no |
| MIC Range： | Susceptible Amikacin: ≤16 µg/mL Ceftazidime: ≤4 µg/mL Doripenem: ≤1 µg/mL Fosfomycin: ≤64 µg/mL Meropenem: ≤1 µg/mL Intermediate Amoxicillin-clavulanate: 16/8 µg/mL Aztreonam: 8 µg/mL Piperacillin-tazobactam: 32/4 - 64/4 µg/mL Resistant Cefepime: ≥16 µg/mL Ceftriaxone: ≥4 µg/mL Ciprofloxacin: ≥4 µg/mL Imipenem: ≤1 µg/mL Levofloxacin: ≥8 µg/mL Tetracycline: ≥16 µg/mL Trimethoprim-sulfamethoxazole: ≥4/76 µg/mL |
| Comments： | This strain is part of the Global Priority Superbugs collection. It is an extensively characterized antimicrobial-resistant clinical isolate with validated genotypic and phenotypic activity against a variety of drug classes. This strain is provided with geographic source information; an NGS-assembled whole genome sequence, including annotated antibiotic resistance and rRNA genes; and an expanded level of susceptibility data with MIC test results. Minimum inhibitory concentration (MIC) ranges for resistant, intermediate, and susceptible are based on criteria within the Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Predicted antimicrobial resistance gene sequence data are provided for informational purposes only and are based on open reading frames (ORFs) identified and annotated from contigs produced during next-generation sequencing (NGS). ATCC does not warrant that the entire predicted antimicrobial resistance gene is present within the sequence prepared for lot-specific reports. Likewise, the information provided merely indicates that some portion of the sequence (whole or in part) is present based on analytical base pair alignment with known gene sequences. |
| Medium： | ATCC® Medium 18: Trypticase Soy Agar/Broth |
| Growth Conditions： | Temperature: 37°C Atmosphere: Aerobic |
| Name of Depositor： | International Health Management Associates (IHMA), Inc. |
| Special Collection： | Global Priority Superbugs |
| Chain of Custody： | ATCC |
| Patient Age： | 78 |
| Patient Gender： | Female |
| References： | Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Wayne, PA. M100S, 2016. |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
Escherichia coli (Migula) Castellani and Chalmers
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Escherichia coli (Migula) Castellani and Chalmers |
|---|---|
| 商品货号： | TS215124 |
| Reports： | Upon your purchase of this product, you will receive a report containing MIC values, a susceptibility profile, and the DNA sequence information for predicted annotated antibiotic resistance genes and 16S rRNA genes. This report will be provided in multiple formats (.pdf, .txt, .xls, .zip). |
| Deposited As： | Escherichia coli |
| Classification： | Enterobacteriaceae, Escherichia |
| Strain Designations： | 1099705 |
| Application： | Drug discovery and development Development of molecular-based detection assays Development of updated sterility protocols |
| Isolation： | Urine |
| Isolation Date： | 2014 |
| Geographic Source： | Czech Republic |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen |
| Storage Conditions： | -80°C or colder |
| Preceptrol®： | no |
| Annotated Genes： | AAC(3)-IIa aadA5 acrA acrB acrD acrE acrF APH(3\)-Ib APH(6)-Id baeR CMY-47 CTX-M-14 emrB emrE macA macB marA mdtB mdtC mdtF mexB msbA TEM-1 tet(G) tolC |
| Type Strain： | no |
| MIC Range： | Susceptible Amikacin: ≤16 µg/mL Ceftazidime: ≤4 µg/mL Doripenem: ≤1 µg/mL Fosfomycin: ≤64 µg/mL Meropenem: ≤1 µg/mL Intermediate Amoxicillin-clavulanate: 16/8 µg/mL Aztreonam: 8 µg/mL Piperacillin-tazobactam: 32/4 - 64/4 µg/mL Resistant Cefepime: ≥16 µg/mL Ceftriaxone: ≥4 µg/mL Ciprofloxacin: ≥4 µg/mL Imipenem: ≤1 µg/mL Levofloxacin: ≥8 µg/mL Tetracycline: ≥16 µg/mL Trimethoprim-sulfamethoxazole: ≥4/76 µg/mL |
| Comments： | This strain is part of the Global Priority Superbugs collection. It is an extensively characterized antimicrobial-resistant clinical isolate with validated genotypic and phenotypic activity against a variety of drug classes. This strain is provided with geographic source information; an NGS-assembled whole genome sequence, including annotated antibiotic resistance and rRNA genes; and an expanded level of susceptibility data with MIC test results. Minimum inhibitory concentration (MIC) ranges for resistant, intermediate, and susceptible are based on criteria within the Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Predicted antimicrobial resistance gene sequence data are provided for informational purposes only and are based on open reading frames (ORFs) identified and annotated from contigs produced during next-generation sequencing (NGS). ATCC does not warrant that the entire predicted antimicrobial resistance gene is present within the sequence prepared for lot-specific reports. Likewise, the information provided merely indicates that some portion of the sequence (whole or in part) is present based on analytical base pair alignment with known gene sequences. |
| Medium： | ATCC® Medium 18: Trypticase Soy Agar/Broth |
| Growth Conditions： | Temperature: 37°C Atmosphere: Aerobic |
| Name of Depositor： | International Health Management Associates (IHMA), Inc. |
| Special Collection： | Global Priority Superbugs |
| Chain of Custody： | ATCC |
| Patient Age： | 78 |
| Patient Gender： | Female |
| References： | Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Wayne, PA. M100S, 2016. |
